Tue, 28th Jul 2020 07:16
July 28 (Reuters) - AstraZeneca Plc said on Tuesday
its diabetes drug Farxiga met the main goal in a late-stage
trial testing the drug's effectiveness in treating patients with
chronic kidney disease.
The trial also met all of its secondary goals in chronic
kidney disease patients with and without type-2 diabetes".
(Reporting by Aakash Jagadeesh Babu in Bengaluru: Editing by
Bernard Orr)
(Alliance News) - Stock prices in London got a boost at midday on Monday, as investors eye a key UK inflation reading later in the week, which is expe...
(Alliance News) - AstraZeneca PLC on Monday announced plans for a USD1.5 billion manufacturing facility in Singapore to produce antibody drug conjugat...
(Alliance News) - London's FTSE 100 is called to open higher at the start of the week, while the pound climbed and gold hit another record high, with ...
(Sharecast News) - AstraZeneca announced plans to construct a $1.5bn manufacturing facility in Singapore on Monday, dedicated to the production of ant...
(Alliance News) - AstraZeneca PLC on Thursday said results from recent trials revealed a significant reduction in cases of Covid-19.
Astrazeneca (AZN)